Abstract:BackgroundPositiveallosteric modulators of GABAA receptors transduce a host ofbeneficial effects but can have motor and sedative liabilities. A benzodiazepine, HZ‐166, had previously been characterized as an alpha 2,3‐selective GABAA receptor modulator with anticonvulsant, anxiolytic, and anti‐nociceptive properties but reduced motor effects. However, the ester moiety in HZ‐166 quickly metabolizes to the carboxylic acid leading to variable exposures of ester in plasma and brain. Moreover, the acid of HZ‐166 possesses significant invitro activity and may well contribute to efficacy seen in in vivo models. We have identified five membered ringheterocycles (oxazoles, dioxazoles) as competent ester replacements which lend themselves to comparable in vitro potency, reduced metabolic complications, consequently leading to an overall increase in unbound central concentration and thus increased efficacy in animal models of pain and epilepsy.MethodsPlasmaand brain exposures of compounds were assessed after i.p. dosing. Compounds were evaluated for efficacy inseveral rodent seizure‐induction models. We also evaluated the anti‐nociceptive effects of one compound (KRM‐II‐81)in rats exposed to chronic pain induced by spinal nerve ligation (SNL) (L5/6)by the Von Frey test. Finally,assessment of motor impairment was evaluated on the inverted screen test.ResultsKRM‐II‐81which utilizes a bioisosteric oxazole as a five membered ring heterocycle replacementof the ester in HZ‐166 did not negatively affect selectivity for α 3(0.97 μM) over α 1 (> 20 μM). However, KRM‐II‐81 demonstrated enhancedbrain exposure versus HZ‐166 after systemic administration. Accordingly, unbound mouse brain exposure exhibited by KRM‐II‐81 after 1 hr (10 mg/kg, i.p.) was 978 nM. In contrast, HZ‐166 possessed >100 folddecrease in mouse unbound brain concentration (6.4 nM) when dosed under the same conditions. Increased central exposure translated to increased efficacy without induction of motor side effects. KRM‐II‐81 (30 mg/kg, i.p.) was fully protective against pentylenetetrazole (PTZ)‐induced clonic convulsions in rats (ED50 = 10.2 mg/kg), whereas HZ‐166 was only partially effective. Further, whereas HZ‐166 (up to 60 mg/kg, i.p.) was ineffective in increasing the dose of i.v.‐infused PTZ required for convulsions, KRM‐II‐81 was efficacious at a dose as low as 10 mg/kg. HZ‐166 was also not active against electroshock‐induced convulsions in mice while KRM‐II‐81 showed efficacy at 30 mg/kg. KRM‐II‐81 also increased pain thresholds by ~2.5 times, an effect equivalent to gabapentin without observable changes in sedation or motor impairment. Brains from SNL rats exhibited decreases in K+‐evoked glutamate release.ConclusionsSubstitution of an oxazole bioisostere for the ester in HZZ‐166 did not affect selectivity α subtype selectivity but significantly increased mouse brain exposure after systemic dosing. Increased brain exposure translated to increased potency and efficacy in rodent seizure‐induction models as well as efficacy against nociceptive challenge in a rodent chronic pain model. In addition, motor side‐effects were not exacerbated by KRM‐II‐81. Thus, KRM‐II‐81 represents a significant advance in the pharmacology of the GABAa receptor.

Antinociceptive effects of α2/α3-subtype selective GABAA receptor positive allosteric modulators KRM-II-81 and NS16085 in rats: behavioral specificity

A question of balance--positive versus negative allosteric modulation of GABA(A) receptor subtypes as a driver of analgesic efficacy in rat models of inflammatory and neuropathic pain

Examining the Effects of (α4)3(β2)2 Nicotinic Acetylcholine Receptor-Selective Positive Allosteric Modulator on Acute Thermal Nociception in Rats

P2X3 and P2X2/3 receptors inhibition produces a consistent analgesic efficacy: A systematic review and meta-analysis of preclinical studies

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.

Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans

Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain

(E)-3-furan-2-yl-N-phenylacrylamide (PAM-4) decreases nociception and emotional manifestations of neuropathic pain in mice by α7 nicotinic acetylcholine receptor potentiation

A Novel, A-2, 3-Selective Gaba(A) Receptor Modulator with Improved Central Penetrability and Associated Antiepileptic and Anti-Pain Efficacy

THE ANALGESIC EFFECTS OF INTRATHECAL ADMINISTRATION OF Ro 25-6981 ON NEUROPATHIC PAIN IN RATS:STUDY ON THE ELECTROPHYSIOLOGICAL MECHANISMS

A Novel Class of Potent, Allosteric Trpa1 Antagonists Reverse Hyperalgesia in Multiple Rat Models of Neuropathic Pain

Modulation of spinal GABAergic analgesia by inhibition of chloride extrusion capacity in mice

Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain.

Effects of neurokinin-1 receptor agonism and antagonism in the rostral ventromedial medulla of rats with acute or persistent inflammatory nociception

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model

Effects of group III metabotropic glutamate receptors subtypes on neuropathic pain

Novel selective κ agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion

Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking

Nonsedating anxiolytics

3D-QSAR, ADME-Tox In Silico Prediction and Molecular Docking Studies for Modeling the Analgesic Activity against Neuropathic Pain of Novel NR2B-Selective NMDA Receptor Antagonists

Effects of Selective and Mixed-Action Kappa and Delta Opioid Receptor Agonists on Pain-Related Behavioral Depression in Mice